Human Anti-NECTIN4 Recombinant Antibody (clone Enfortumab)

Figure 1 AGS-22M6 antibody specifically recognizes cell-surface human nectin-4 and its orthologs.

Cell counts of PC-3 cells expressing human, monkey, and rat nectin-4 (open histograms) were overlaid against mocktransfected PC-3 cells (solid histogram).

Challita-Eid, P. M., Satpayev, D., Yang, P., An, Z., Morrison, K., Shostak, Y., ... & Capo, L. (2016). Enfortumab vedotin antibody–drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models. Cancer research, 76(10), 3003-3013.

Figure 2 FC measures the binding of AGS-22M6 antibody to human nectin-4.

Saturation curve of AGS-22M6 and AGS-22M6E binding to nectin-4 expressed on T-47D by flow cytometry shows KD of 0.01 nmol/L. MFI, mean fluorescence intensity

Challita-Eid, P. M., Satpayev, D., Yang, P., An, Z., Morrison, K., Shostak, Y., ... & Capo, L. (2016). Enfortumab vedotin antibody–drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models. Cancer research, 76(10), 3003-3013.

Figure 3 AGS-22M6E ADC shows potent and specific in vitro cytotoxicity.

PC-3 cells engineered to express human were incubated with increasing concentrations of unconjugated AGS-22M6.

Challita-Eid, P. M., Satpayev, D., Yang, P., An, Z., Morrison, K., Shostak, Y., ... & Capo, L. (2016). Enfortumab vedotin antibody–drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models. Cancer research, 76(10), 3003-3013.

Figure 4 T-47D breast cancer cells were killed by AGS-22M6E ADC.

T-47D breast cancer cells, were incubated with increasing concentrations of unconjugated AGS-22M6.

Challita-Eid, P. M., Satpayev, D., Yang, P., An, Z., Morrison, K., Shostak, Y., ... & Capo, L. (2016). Enfortumab vedotin antibody–drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models. Cancer research, 76(10), 3003-3013.

Figure 5 Nectin-4–targeted ADC shows significant tumor growth inhibition in multiple xenograft models.

AG-B1 subcutaneous xenografts treated with AGS-22M6E (or controls) at 0.8 mg/kg.

Challita-Eid, P. M., Satpayev, D., Yang, P., An, Z., Morrison, K., Shostak, Y., ... & Capo, L. (2016). Enfortumab vedotin antibody–drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models. Cancer researc 76(10), 3003-3013.

Figure 6 AGS-22M6E ADC shows significant tumor growth inhibition in multiple xenograft models.

AG-Br7 orthotopic xenografts treated with AGS-22M6E (or controls) at 5 mg/kg.

Challita-Eid, P. M., Satpayev, D., Yang, P., An, Z., Morrison, K., Shostak, Y., ... & Capo, L. (2016). Enfortumab vedotin antibody–drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models. Cancer researc 76(10), 3003-3013.